A-to-Z enrolled 4497 subjects after ACS and randomized them to a high-potency ( simvastatin 40 mg/day 1 months , then simvastatin 80 mg/day ) versus a delayed moderate-potency statin strategy ( placebo 4 months , then simvastatin 20 mg/day ) .